Johnson and Johnson looking like an underrated blue chip stock. I'm thinking buy. It's got all the hallmarks of an undervalued, solid foundation. The yield is just under 3% which is higher than the S&P500, but the company carries a fraction of the risk. If you put $10,000 today, the compounding interest would accumulate into deep six figures over two decades. And for what risk? That people stop getting sick?
Johnson & Johnson
JNJ
NYSE
IPO1944
about JNJ
Johnson & Johnson is a global healthcare company that focuses on the development and sale of pharmaceuticals and medical technology. Its pharmaceutical division, known as Innovative Medicine, creates prescription drugs for a wide range of diseases, while its MedTech division manufactures and sells a broad portfolio of surgical equipment, orthopedic products, and other medical devices.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $193.36 | $195.54 | $193.07 | $453.94B | 8.80M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$2.14 | 19.38 | 19.74 | 31.23% | 21.47% | 2.67% |
